Gilead Sciences (GILD.US) announced that it had struck a licensing agreement to produce the antiviral drug remdesivir in 127 countries, not including the US. The company’s will work with five generic drugmakers to produce the potential drug for coronavirus. Among them is Mylan (MYL.US), which is the world's largest producer of generic drugs.

Gilead Sciences (GILD.US) shares rose 1.96% in pre-market trading. If positive mood persists, then resistance at $86.16 per share may be tested. Source: xStation5
Ross Stores: "Only" good earnings, or a recession signal?
US OPEN: The market takes a shallow breath after intervention in US debt
Market Wrap: European Indices Rise, CTS Eventim Falls After Earnings 🚩 Metals Gain Amid Bond Market Strains
Daily Summary: Dollar Recovers Losses, Oil Near 3-Week Highs 🗽 US30 Falls 1%